Forte Biosciences FB102 shows vitiligo improvement in phase 1b trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
July 9, 2026 8:00 AM EDTStatistically Significant FB102 Benefit Observed By Day 64 and Continued through Week 24
FB102-Treated Subjects Continued Improving Through Week 24 After Completion of the 12-Week Treatment Period Supporting FB102 Mechanistic Modulation of Both IL-2 and IL-15Dependent Pathogenic T-cell Biology while Preserving Regulatory T Cells
Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET
DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc.... More
